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by sEH, when AA concentrations were low (1 μM) or epoxy-
genase activity was curbed by modulating NADPH. With 
increasing AA concentrations sEH became more dominant 
and with 30 μM AA produced twice the level of DHETs 
compared to mEH. Immunohistochemistry of C57BL/6 liver 
slices further revealed that mEH expression was more wide-
spread than sEH expression. mEH immunoreactivity was 
detected in hepatocytes, Kupffer cells, endothelial cells, and 
bile duct epithelial cells, while sEH immunoreactivity was 
confined to hepatocytes and bile duct epithelial cells. Finally, 
transcriptome analysis of WT, mEH KO, and sEH KO liver 
was carried out to discern transcriptional changes associated 
with the loss of EH genes along the CYP-epoxygenase–EH 
axis. We found several prominent dysregulations occurring 
in a parallel manner in both KO livers: (a) gene expression of 
Ephx1 (encoding for mEH protein) was increased 1.35-fold 
in sEH KO, while expression of Ephx2 (encoding for sEH 
protein) was increased 1.4-fold in mEH KO liver; (b) Cyp2c 
genes, encoding for the predominant epoxygenases in mouse 
liver, were mostly dysregulated in the same manner in both 
sEH and mEH KO mice, showing that loss of either EH has a 
similar impact. Taken together, mEH appears to play a lead-
ing role in the hydrolysis of 8,9-EET and 9,10-EpOME and 
also contributes to the hydrolysis of other FA epoxides. It 
probably profits from its high affinity for FA epoxides under 
non-saturating conditions and its close physical proximity to 
CYP epoxygenases, and compensates its lower abundance by 
a more widespread expression, being the only EH present in 
several sEH-lacking cell types.
Keywords Microsomal epoxide hydrolase · Liver · EET · 
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Abstract Microsomal and soluble epoxide hydrolase 
(mEH and sEH) fulfill apparently distinct roles: Whereas 
mEH detoxifies xenobiotics, sEH hydrolyzes fatty acid (FA) 
signaling molecules and is thus implicated in a variety of 
physiological functions. These epoxy FAs comprise epox-
yeicosatrienoic acids (EETs) and epoxy-octadecenoic acids 
(EpOMEs), which are formed by CYP epoxygenases from 
arachidonic acid (AA) and linoleic acid, respectively, and 
then are hydrolyzed to their respective diols, the so-called 
DHETs and DiHOMEs. Although EETs and EpOMEs are 
also substrates for mEH, its role in lipid signaling is con-
sidered minor due to lower abundance and activity relative 
to sEH. Surprisingly, we found that in plasma from mEH 
KO mice, hydrolysis rates for 8,9-EET and 9,10-EpOME 
were reduced by 50% compared to WT plasma. This strongly 
suggests that mEH contributes substantially to the turnover 
of these FA epoxides—despite kinetic parameters being in 
favor of sEH. Given the crucial role of liver in controlling 
plasma diol levels, we next studied the capacity of sEH and 
mEH KO liver microsomes to synthesize DHETs with vary-
ing concentrations of AA (1–30 μM) and NADPH. mEH-
generated DHET levels were similar to the ones generated 
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Abbreviations
AA  Arachidonic acid
CL  Centrilobular
CYP  Cytochrome P450
EC  Endothelial cell
EET  Epoxyeicosatrienoic acid
EH  Epoxide hydrolase
EpOME  Epoxy-octadecenoic acid
FA  Fatty acid
DiHOME  Dihydroxy-octadecenoic acid
DHET  Dihydroxy-eicosatrienoic acid
DMBA  7,12-Dimethylbenz[a]anthracene
fdr  False discovery rate
HETE  Hydroxyeicosatetraenoic acid
mEH  Microsomal epoxide hydrolase
NSPA  2-Nonylsulfanyl-propanamide
PP  Periportal
PV  Portal vein
sEH  Soluble epoxide hydrolase
tAUCB  Trans-4-[4-(3-adamantan-1-y1-ureido)-
cyclohexyloxy]-benzoic acid
TCPO  1,1,1-Trichloropropene oxide
Introduction
Microsomal epoxide hydrolase (mEH) and soluble epox-
ide hydrolase (sEH) belong to the epoxide hydrolase (EH) 
family, which catalyzes the hydrolysis of epoxides. mEH 
and sEH were first characterized as detoxifying enzymes, 
because they can convert genotoxic epoxides to less harm-
ful dihydrodiols (Oesch 1973; Ota and Hammock 1980). 
In particular, numerous in vitro and in vivo studies provide 
evidence that mEH is a crucial enzyme in xenobiotic detoxi-
fication with its substrates comprising epoxide intermediates 
from chemicals (e.g., styrene, 1,2-butadiene) and pharma-
ceuticals (e.g., phenytoin, carbamazepine, oprozomib) (Fret-
land and Omiecinski 2000; Wang et al. 2017). However, 
its role in the metabolism of endogenous lipid epoxides is 
less clear. Older studies suggested a potential function for 
mEH in steroid biosynthesis, because it is able to hydro-
lyze epoxy steroids (Vogel-Bindel et al. 1982) and partici-
pates in the antiestrogen binding site (Mesange et al. 1998). 
More recently, certain polymorphisms of the human mEH 
gene, EPHX1, have been associated with an increased risk 
to develop preeclampsia, a severe pregnancy complication, 
characterized by hypertension (Groten et al. 2014; Laasanen 
et al. 2002; Pinarbasi et al. 2007; Zusterzeel et al. 2001).
By contrast, a large body of evidence demonstrates the 
involvement of sEH in various physiological processes, 
which is due to the ability of sEH to efficiently hydrolyze 
endogenous FA epoxides such as the AA-derived epox-
yeicosatrienoic acids (EETs) (Yu et al. 2000) and linoleic 
acid-derived epoxy-octadecenoic acids (EpOMEs, also 
termed leukotoxins) (Moghaddam et al. 1997). EETs are 
generated in a cytochrome P450 (CYP)-epoxygenase-medi-
ated reaction, in which each of the four AA double bonds 
can be oxidized and thus four epoxide-regioisomers are 
formed (5,6-, 8,9-, 11,12-, and 14,15-EET). EETs are strong 
vasodilators in various vessel beds (Fisslthaler et al. 1999) 
and exert angiogenic (Michaelis and Fleming 2006), anti-
inflammatory (Node et al. 1999), antinociceptive (Inceoglu 
et al. 2008), and tissue-regenerating and -protective effects 
(Panigrahy et al. 2013). Their diols (dihydroxyeicosatrienoic 
acids, DHETs) are generally regarded as being less active, 
and sEH-mediated hydrolysis is thus thought to control lev-
els of active EETs. By contrast, diols derived from EpOMEs, 
termed dihydroxy-EpOMEs or DiHOMEs, are more potent 
than their parental epoxides and display pro-inflammatory 
properties. They cause edematous lung injury in mammals 
(Moghaddam et al. 1997) and possibly contribute to acute 
respiratory distress syndrome (Zheng et al. 2001). Although 
mEH is also capable of metabolizing EETs and EpOMEs 
(Decker et al. 2012; Marowsky et al. 2009, 2016), endog-
enous epoxy FA metabolism seems clearly dominated by 
sEH due to its higher activity relative to mEH (Kodani and 
Hammock 2015; Spector and Kim 2015). Based on the 
maximal velocity Vmax, which indicates how many moles 
of epoxide are metabolized per gram enzyme in a minute 
under saturating conditions, human sEH is 170 times faster 
than mEH in hydrolyzing 14,15-EET (Decker et al. 2012), 
and mouse sEH is even 800 times faster than mEH with the 
same substrate (Marowsky et al. 2009). sEH and mEH are 
also distinct in their preference profiles, as human and mouse 
sEH show highest catalytic efficiencies (in descending order) 
with 14,15-EET > 9,10-EpOME > 12,13-EpOME > 11,12-
EET ≫ 8,9-EET (Morisseau et al. 2010; Newman et al. 
2002). Available data for mEH are limited to EETs, and 
indicate an inverse preference profile relative to sEH, as 
human and mouse mEH show highest catalytic efficacies 
with 11,12-EET > 8,9-EET > 14,15-EET (Decker et al. 
2012; Marowsky et al. 2009).
In line with the major role of sEH in EET hydrolysis, 
inhibition of sEH or genetic deletion of Ephx2, the gene 
encoding for sEH, results in increased EET levels and mod-
ifications of various EET-mediated physiological effects 
including blood pressure (Sinal et al. 2000; Sun et al. 2014), 
inflammation (Bettaieb et al. 2014; Kim et al. 2015; Tao 
et al. 2016), and inflammatory pain (Inceoglu et al. 2006). 
In contrast to sEH inhibitors, which elaborated over recent 
years (Morisseau et al. 1999; Ulu et al. 2012), the available 
mEH inhibitors have the disadvantage that they are either 
highly unstable [2-nonylsulfanyl-propanamide (NSPA) and 
elaidamide each contain an amide group and are readily 
metabolized by amide hydrolases (Morisseau et al. 2008)] 
or highly toxic (1,1,1-trichloropropene oxide, TCPO), which 
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prevents their application in vivo. In absence of stable and 
well-tolerated mEH inhibitors, mEH KO mice provide a use-
ful tool to assess the physiological importance of mEH. Yet 
mEH KO mice lack an obvious phenotype (Miyata et al. 
1999) and mEH KO characterization has so far focused 
exclusively on aberrant effects in xenobiotic metabolism 
with compounds such as styrene (Carlson 2010), DMBA 
(Miyata et al. 1999; Rajapaksa et al. 2007), and benzene 
(Bauer et al. 2003). Here, we expand on the phenotypic char-
acterization of mEH KO mice by focusing on changes in 
endogenous epoxy FA metabolism, using plasma and liver 
homogenates as physiological samples. These data were 
correlated with liver transcriptome data from WT control, 
sEH KO, and mEH KO mice with focus on differentially 
expressed genes underlying the CYP epoxygenase–epoxide 
hydrolase system. Finally, the hepatic expression pattern of 
mEH and sEH protein expression was investigated.
Materials and methods
sEH KO (Sinal et al. 2000) and mEH KO mice (Miyata et al. 
1999) were kindly provided by Dr. F. J. Gonzalez (NIH, 
Bethesda, MD, USA). Both KO lines were backcrossed for 
7–9 generation onto C57BL/6 background prior to this study 
and preliminary experiments were conducted with WT lit-
termates from both lines. Since no difference was detected 
between sEH and mEH WT littermates in CYP-epoxyge-
nases/EH-dependent metabolism, WT mice from both lines 
were used for all experiments presented in the current study. 
All mice were housed in single-ventilated cages in facili-
ties, which met the criteria for specific pathogen conditions 
(SPF); animals were kept at a standard 12:12 h light cycle 
and had ad  libitum access to water and standard chow. 
Except for immunohistochemical experiments, exclusively 
male mice (8–16 weeks of age) were used for this study. 
For immunohistochemistry, liver slices were obtained from 
both male and female mice (8–16 weeks of age). All pro-
cedures were approved by the local veterinary authorities 
and were performed in accordance with the European Com-
munity Council Directive (86/609/EEC). Experiments were 
designed to minimize the number of animals used and their 
suffering, according to the guidelines of the Swiss Academy 
of Medical Sciences.
Genotyping
mEH KO, sEH KO, and WT genotype were confirmed by 
standard polymerase chain reaction (PCR), using specific 
primer pairs. Genomic DNA was extracted from mouse ear 
biopsies and the following primers were used to identify 
homozygous WT and mEH KO mice: mKO forward 5′-CCC 
GGG ACA AGG AGG AGA CC-3′ and mKO reverse 5′-AAG 
GAT CAC AGG GTG AAA GGAA-3′. The PCR product for 
homozygous WT had a size of 800 bp and that for homozy-
gous mEH KO mice a size of 1400 bp. For genotyping sEH 
KO mice, the primers sKO forward 5′-GCG AGG GGC GGT 
GCT GAG ATTGG-3′ and sKO reverse 5′-CTG GAA AGC 
AAT TTG AAA CCT GGG -3′ were used. The PCR product 
for homozygous WT had a size of 305 bp, for homozygous 
sEH KO a size of 1444 bp.
Plasma and liver oxylipin profiles
Animals were killed by i.p. injection of 160–200 μl Sodium-
Pentobarbital (50 mg/ml). Blood was immediately taken 
from V. cava, using a syringe that was rinsed before with 
10% EDTA (pH 8). The collected blood was centrifuged 
for 10 min at 1700×g in a benchtop centrifuge (Eppen-
dorf 5417R); plasma was removed and frozen at −20 °C 
after adding the antioxidant butylated hydroxytoluene. For 
oxylipin extraction, 150 μl of plasma was added to 150 μl 
acetonitrile/methanol (1:1), including the deuterated stand-
ards for 8,9-, 11,12-, 14,15-EETs and DHETs; 9,10-, and 
12,13-EpOMEs; and 5-, 8-, and 12-HETEs. After addition 
of 700 μl phosphate-buffered saline (PBS, pH 7.4), the sam-
ples were centrifuged (5 min, 10,000×g) and subjected to 
solid-phase extraction, using  ISOLUTE® C18 solid-phase 
extraction columns (100 mg sorbent mass; Biotage, Upp-
sala, Sweden). The columns were primed with 2 × 1 ml 
acetonitrile and 2 × 1 ml PBS containing 5% methanol 
(pH 7.4). After loading the samples, columns were washed 
with 1 ml PBS containing 5% methanol, dried, and eluted 
with 3 × 600 μl ethyl acetate. The eluate was dried under 
nitrogen, and extracted lipids were re-dissolved in 100 μl 
methanol/20 mM Tris, pH 7.4 (1:1), and subjected to liquid 
chromatography-tandem mass spectrometry (LC–MS/MS). 
Incubation of liver homogenates with 50 μM AA was carried 
out as described previously (Marowsky et al. 2016).
Preparation of hepatic microsomal and cytosolic 
fractions
100–200 mg frozen livers of all three genotypes (WT, mEH 
KO, sEH KO) were homogenized on ice in 1 ml buffer 
containing 125 mM KCl, 250 mM sucrose, 100 mM potas-
sium phosphate, and 1 mM EDTA (pH 7.4). The samples 
were centrifuged (5 min at 600×g; 20 min at 9000×g); the 
supernatant (S9 fraction) was removed and further centri-
fuged for 20 min at 100,000×g in an ultracentrifuge, using a 
TLA-100.3 rotor (Beckman Coulter, Brea, CA, USA), which 
yielded the cytosolic fraction as supernatant. The pellet, con-
taining the microsomal fraction, was washed in 500 µl Tris 
buffer (0.1 M Tris, 0.125 M KCl, pH 7.4), ultra-centrifuged 
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again for 20 min at 100,000×g, and resuspended in Tris 
buffer. The final microsomes were homogenized and shock-
frozen in liquid nitrogen. The total protein content of micro-
somal and cytosolic fractions was determined using a stand-
ard Bradford protein assay.
Turnover assays with EETs and selective EH inhibitors
Cytosolic (0.2–0.3 μg total protein) or microsomal fractions 
(3–10 μg total protein) were added to a final volume of 50 μl 
of Tris buffer (10 mM Tris, 100 mM NaCl, 1 mM EDTA, 
pH 7.4) and preincubated on ice for 10 min with and without 
the selective sEH inhibitor trans-4-[4-(3-adamantan-1-y1-
ureido)-cyclohexyloxy]-benzoic acid (tAUCB; 1 μM) or a 
combination of the mEH inhibitors 1,1,1-trichloropropene 
oxide (TCPO; 1 mM), and 2-nonylsulfanyl-propanamide 
(NSPA; 10 μM) (Morisseau et al. 2008). The reactions were 
started by adding 10 μM 14,15-EET as substrate to cytosolic 
fractions or 2–4 μM 11,12-EET to microsomes, and sam-
ples were incubated for 10 min at 37 °C. The reactions were 
stopped by adding 50 µl acetonitrile and subsequently 100 µl 
 ddH2O containing the deuterated standards for the respective 
EETs and DHETs. Samples were centrifuged and analyzed 
without extraction by LC–MS/MS.
Epoxygenase‑epoxide hydrolase activity assay 
with microsomes
Microsomes (containing 50 μg protein) were added to a final 
vol of 50 μl buffer (50 mM Tris, pH 7.4, 10 mM  MgCl2, 
150 mM KCl, and 8 mM sodium isocitrate). The reaction 
was started by adding 2 mM NADPH, 0.6 U/mL isocitrate 
dehydrogenase Type IV, and AA. Samples were incubated 
at 37 °C for 10–30 min. The reactions were stopped with 
100 μl ethyl acetate containing deuterated standards. The 
organic phase was removed and samples were extracted a 
second time with 100 μl ethyl acetate. Organic phases were 
combined and dried under nitrogen. Lipids were re-dissolved 
in Tris (20 mM, pH 7.4) and analyzed by LC–MS/MS.
Western blot analysis
Frozen liver samples (200 mg) from WT and mEH KO mice 
were homogenized in 10 vol RIPA lysis buffer (20 mM Tris, 
150 mM NaCl, 1% Triton X-100, 1% Na-deoxycholate, 0.1% 
SDS, 1 Protease inhibitor cocktail tablet (Complete Mini, 
Roche, Basel, Switzerland)), and centrifuged in a bench-
top centrifuge for 10 min at 13,000×g. The cleared sample 
was assayed for total protein content using the Bradford 
method. Samples (20 μg of protein per lane) were separated 
on a 12.5% SDS-PAGE and transferred onto PVDF mem-
branes (Immobilon-P, Millipore, Billerica, MA, USA) using 
the semi-dry Trans-Blot®Turbo™ Transfer Starter System 
(BioRad, Hercules, CA, USA). The primary antibodies used 
were raised in rabbits against rat sEH [in-house (Marowsky 
et al. 2009)] and against mouse GAPDH (Sigma-Aldrich, 
St. Louis, MO, USA), each applied in dilutions of 1:10,000. 
The secondary antibody used was raised in donkey against 
rabbit IgG and fluorescent-labeled (1:8000,  IRDye® 800CW 
Donkey anti-Rabbit IgG, Li-cor Biosciences, Lincoln, NE, 
USA). Fluorescence of immunoreactive bands was detected 
at 800 nm with an Odyssey IR imager (Li-cor Biosciences, 
Lincoln, NE, USA), followed by quantification of band 
intensities with Odyssey IR imager software (Image Studio 
3.1).
Histology
Animals were euthanized by  CO2 asphyxiation. The liver 
was quickly removed and fixed in 4% neutral-buffered for-
malin (Formafix, Hittnau, Switzerland). Sections of the left 
lateral and median lobes were dehydrated through graded 
alcohols and embedded in paraffin wax. Consecutive sec-
tions (3–5 µm) were prepared, mounted on glass slides, and 
subjected to immunohistochemistry (IHC). IHC was per-
formed using rabbit anti-mEH (directed against a mixture 
of rat, mouse, and human mEH protein, made in-house) and 
rabbit anti-sEH antibody (Marowsky et al. 2009). Briefly, 
sections were deparaffinised in xylene and rehydrated in 
decreasing concentrations of ethanol. Sections underwent 
antigen retrieval by incubation with 10 mM citrate buffer 
(pH 6.0). For mEH IHC, slides were incubated for 1 h at 
37 °C with the primary antisera (1:2000, diluted in Dako 
antibody diluent, Dako-Agilent Technologies, Denmark), 
whilst incubation with the anti-sEH antibody (1:1500) 
occurred overnight at 4 °C. In both staining procedures, 
this was followed by incubation for 30 min with a horse 
radish peroxidase (HRP)-labeled polymer, conjugated to a 
secondary anti-rabbit antibody (Dako EnvisionTM System, 
Dako-Agilent Technologies). The reaction was visualized 
using 3,3′-diaminobenzidine (DAB) as chromogen, fol-
lowed by light counterstain with hematoxylin. After rins-
ing, slices were dehydrated in ascending concentrations of 
ethanol, cleared with xylene, cover-slipped, and mounted. 
All immunohistological stainings were performed using 
an Autostainer (Dako Autostainer Universal Staining Sys-
tem Model LV-1, Dako-Agilent Technologies). Slides were 
scanned using a digital slide scanner (NanoZoomer-XR 
C12000; Hamamatsu, Japan) and pictures were taken using 
the NDP.view2 viewing Software (U12388-01, Hamamatsu).
LC–MS/MS analysis of oxylipins
Analysis of eicosanoid profiles was performed as estab-
lished previously (Marowsky et  al. 2016). 2.5  ng of 
each of the following compounds served as standard for 
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quantification: 8,9-EET, 11,12-EET, 14,15-EET, 5,6-
DHET, 8,9-DHET,11,12-DHET, 14,15-DHET, 9,10-
EpOME, 12,13-EpOME, 5-HETE, 8-HETE, 12-HETE, 
20-HETE, AA, 8,9-EET-d11, 11,12-EET-d11, 14,15-EET-
d11, 8,9-DHET-d11, 11,12-DHET-d11, 14,15-DHET-d11, 
5-HETE-d8, 12-HETE-d8, 20-HETE-d6, AA-d8. Deuter-
ated standards, 3 ng of each, were added to each experi-
mental sample and served as internal standards. Quan-
tification was done by determining the area under curve 
(AUC) using MultiQuant Software 2.1.1 (Sciex, USA). 
Values were corrected for extraction efficiency and change 
in MS sensitivity by using the internal standard peak area. 
For verification, a sample containing 250 pmol of epoxides 
(EETs or EpOMEs) in Tris buffer (20 mM, pH 7.4) was 
injected in parallel to a sample, in which 250 pmol epoxide 
was completely metabolized by recombinant sEH before. 
The AUC for the diol was then assumed to correspond to 
250 pmol and values were accordingly calculated.
Liver transcriptome analysis
Total RNA from sEH KO, mEH KO, and WT liver (n = 3 
for each) was extracted using a commercially available 
isolation kit. All following steps (purification of mRNA, 
transcription into cDNA and generation of a library) were 
carried out by the Functional Genomic Center of the Uni-
versity of Zurich (FGCZ), following the TruSeq Stranded 
mRNA sample protocol from Illumina (San Diego, Ca, 
USA). Bioinformatic analysis was performed using the R 
package DezRun (https://github.com/uzh/ezRun) within the 
data analysis framework SUSHI (Hatakeyama et al. 2016). 
The raw reads were quality-checked using FastQC (http://
www.bioinformatics.babraham.ac.uk/projects/fastqc/) and 
FastQ Screen (http://www.bioinformatics.babraham.ac.uk/
projects/fastq_screen/). Quality controlled reads (adaptor 
trimmed, first 3 bases hard-trimmed, minimum tail qual-
ity Q20, minimum read length 20 nt) were aligned to the 
reference genome (Ensembl GRCm38.p3) using the STAR 
aligner. Expression counts were computed using countOver-
laps function in the Bioconductor package GenomicRanges. 
Differential expression analysis was performed using the 
edgeR package with raw read counts normalized using the 
trimmed mean of M values method; differential expression 
was computed using the Generalized Linear Mode likeli-
hood ratio test. Project accession number: PRJEB21957.
Materials
All fatty acids used in this study were purchased without 
exception from Cayman Chemicals, Ann Arbor, MI, USA. 
TCPO was purchased from EGA-Chemie (Steinheim, Ger-
many). tAUCB and NSPA were kind gifts from Christophe 
Morisseau, University of California, Davis, CA, USA.
Results
Fatty acid epoxide:diol ratios in plasma of WT, mEH 
KO, and sEH KO animals
To test for a possible impact of mEH on epoxide FA metab-
olism, we compared WT and mEH KO oxylipin profiles 
in plasma; in addition, the sEH KO plasma profile was 
assessed. LC–MS/MS analysis encompassed AA-derived 
EETs, linoleic acid-derived 9,10- and 12,13-EpOMEs 
as well as the respective EH metabolites, namely DHETs 
and DiHOMEs. Furthermore, AA-derived monohydroxy 
metabolites (HETEs) were determined to elucidate pos-
sible secondary effects associated with mEH deficiency. 
All analytes were detectable in appreciable amounts. Com-
pared to WT diol levels, mEH KO had significantly lower 
8,9-DHET and 9,10-DiHOME levels (Fig. 1a, b). Impor-
tantly, diol:epoxide ratios (reflecting hydrolysis rates) for 
8,9-DHET:EET and 9,10-DiHOME: EpOME (Fig. 1c, d) 
were also significantly reduced, suggesting that mEH plays 
an important role in the hydrolysis of 8,9-EET and 9,10-
EpOME in vivo. By contrast, ratios for 14,15-DHET:EET 
and 12,13-DiHOME:EpOME were significantly increased in 
mEH KO relative to WT plasma, an indication for increased 
rather than decreased EH activity. Levels of 5-, 8-, 12-, 15-, 
and 20-HETE were similar in WT, mEH KO, and sEH KO 
plasma (Fig. 1e) (for detailed data and statistics see Suppl. 
Table 1). Results in this and the following figures are shown 
as average values ± SEM (standard error of the mean).
Plasma EET levels were reported to be largely con-
trolled by hepatic sEH activity (Schuck et al. 2014). Thus, 
we hypothesized that increased hydrolysis of the sEH-pre-
ferred substrate 14,15-EET could be attributable to modified 
hepatic sEH activity in mEH KO liver. To investigate this 
further, we determined sEH activity and protein expression 
in mEH KO and WT liver.
sEH activity and protein expression levels in mEH KO 
and WT control liver
Cytosolic fractions from WT and mEH KO liver were pre-
pared and hydrolysis rates with 14,15-EET as substrate 
were determined in the absence and the presence of the sEH 
inhibitor tAUCB (1 μM). The formation rate of 14,15-DHET 
in mEH KO cytosol was significantly higher (1.4-fold) than 
in WT; in both genotypes, formation of 14,15-DHET could 
almost completely be blocked (97%) by the sEH-specific 
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inhibitor tAUCB (Fig.  2a). Furthermore, immunoblot-
ting WT and mEH KO liver with a specific sEH antibody 
revealed that sEH protein expression was 1.3-fold higher in 
mEH KO compared to WT (Fig. 2b, c). Thus, sEH expres-
sion and activity are significantly increased in mEH KO rela-
tive to WT liver.
Oxylipin profiles of WT, mEH KO, and sEH KO liver
Given the unexpected upregulation of sEH in mEH KO 
liver, we next assessed the genotype-specific capacity to 
generate epoxygenase- and EH-mediated products in liver. 
sEH KO, mEH KO and WT liver homogenates were incu-
bated with a high concentration of AA (50 μM) in the pres-
ence of a NADPH-regenerating system, and EET, DHET, 
EpOME, and DiHOME formation rates were analyzed. 
For each metabolite, the respective background level was 
determined in liver homogenates without addition of AA; 
these levels were then subtracted for the calculation of 
the final formation rate. Under these conditions, EET and 
EpOME levels were only detectable in absence of sEH, 
underlining the high capacity of the enzyme. To ascertain 
that the only EHs present in C57BL/6 WT liver are mEH 
and sEH, we incubated WT liver with a mixture containing 
2 µM of each 8,9-, 11,12-, and 14,15-EET in absence and 
presence of the sEH inhibitor tAUCB alone (1 µM) and 
tAUCB (1 µM) in combination with the mEH inhibitors 
TCPO (1 mM) and NSPA (10 µM). tAUCB blocked 50% 
of the turnover to 8,9-DHET, tAUCB and TCPO/NSPA 
together 95% (Fig. 3g) with the residual turnover probably 
due to incomplete block by tAUCB as observed earlier 
in Fig. 2a. Similar results were obtained for 11,12- and 
14,15-EET (data not shown). These findings indicated that 
with high probability no EH other than mEH and sEH 
are expressed in WT liver. In sEH KO liver, mEH is with 
high probability the only EH present and thus responsi-
ble for total FA epoxide hydrolysis (see next paragraph 
and discussion). The mEH-mediated diol formation in 
sEH KO liver was substantial and reached 61% for 8,9-
DHET, 80% for 11,12-DHET, and 43% for 14,15-DHET 
relative to WT (Fig. 3a). Surprisingly, the formation rate 
of 9,10-DiHOME was even higher in sEH KO than in WT 
(134%), while the 12,13-DiHOME formation rate only 
reached 14% of the one in WT (Fig. 3c, d). With regard 
to HETEs, the formation rates were the same for all geno-
types including the one for the vasoconstrictor 20-HETE 
(Fig. 3h, Suppl. Table 2).
Since in most studies an excess of AA is used to deter-
mine genotype-specific differences, we wondered to what 
extent epoxygenase and EH activities would be changed with 
varying AA concentrations. Particularly, we wanted to know 
how mEH and sEH activities adapt to varying degrees of 
epoxygenase activity. Since MS analysis revealed already 
high amounts of free AA levels in all liver homogenate sam-
ples, we switched to liver microsomes for these experiments, 
as these would allow for a better manipulation of experi-
mental parameters. sEH KO and mEH KO liver microsomes 
were chosen, assuming that they contain exclusively one 
type of EH. This was tested in turnover assays with 11,12-
EET as substrate in absence and presence of the selective 
sEH inhibitor tAUCB (mEH KO microsomes) and the selec-
tive mEH inhibitors TCPO/NSPA (sEH KO microsomes). 
tAUCB reduced diol formation in mEH KO microsomes 
by 98% (Fig. 4c), TCPO/NSPA in sEH KO microsomes by 
97% (Fig. 4d), respectively, confirming that indeed exclu-
sively sEH or mEH constitute the remaining EHs in these 
microsomes.
In a first AA experiment, KO liver microsomes were incu-
bated with different concentrations of AA (1, 10, 30 μM) 
for 10, 30, and 60 min in presence of a regenerating system 
(isocitrate/isocitrate dehydrogenase) and 2 mM NADPH 
to guarantee permissive conditions for epoxygenases. The 
sum of generated [EETs and DHETs] was assumed to reflect 
epoxygenase activity, which increased steadily over time and 
with increasing AA concentrations. Epoxygenase activity 
was similar for mEH and sEH KO microsomes and neither 
genotype showed any indication for epoxygenase saturation, 
as concentration curves were linear with a constant slope 
(Fig. 4a, b). For the next experiments, incubation time was 
set to 10 min and mEH and sEH KO microsomes were again 
incubated with varying AA concentrations. With regard to 
DHET formation, sEH and mEH KO microsomes showed 
similar rates for 8,9- and 11,12-DHET, when lower AA con-
centrations (1 and 10 μM) were provided. But with increas-
ing AA concentrations, the difference between the two 
genotypes increased drastically (Fig. 4e–g) until the DHET 
profile looked similar to the one with liver homogenates 
and 50 μM AA, as shown in Fig. 4a. Finally, in an alterna-
tive attempt to curb epoxygenase activity, we incubated the 
microsomes with 30 μM AA, but omitted the regenerating 
system including NADPH (Fig. 4h). Under these conditions, 
DHET formation rate was approx. 40 times lower than with 
regenerating system plus NADPH and mEH KO and sEH 
KO generated similar amounts of diols, indicating that mEH 
and sEH are equally efficient in hydrolyzing epoxides under 
these conditions.
mEH and sEH distribution in mouse liver
To investigate in detail the distribution pattern of mEH and 
sEH in the mouse liver, IHC was applied to formalin-fixed 
paraffin-embedded liver sections obtained from both genders 
from C57BL/6 WT control, mEH KO, and sEH KO animals. 
In accordance with earlier studies (Kawabata et al. 1981), we 
found evidence of zonal distribution for both mEH and sEH 
with higher expression in hepatocytes in the perivenous and 
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weaker expression in the periportal region. Overall, mEH had 
a more homogenous and widespread distribution compared 
to sEH. In addition to hepatocytes, mEH was also expressed 
in endothelial cells lining the branches of the hepatic artery 
and portal vein, Kupffer cells, and bile duct and gall bladder 
epithelial cells (Fig. 5a, b, g–i). sEH expression was confined 
to hepatocytes and epithelial cells of bile ducts and gall blad-
der (Fig. 5d, e). Distribution patterns for both mEH and sEH 
were similar in male and female mice. Furthermore, there was 
no difference in the sEH distribution pattern between WT and 
mEH KO livers, nor in the mEH distribution pattern between 
WT and sEH KO livers. Immunohistochemical stainings 
for mEH and sEH on livers of the correspondent KO mice 
showed no unspecific staining, confirming the specificity of 
the respective sEH and mEH antibody (Fig. 5c, f).
Transcriptome analysis
Finally, the complete liver transcriptomes from C57BL/6 WT 
control, sEH KO, and mEH KO were compared to gain fur-
ther insight on transcriptional effects caused by the deletion 
of EH gene transcripts (see Suppl. Table 3 and 4 for a list of 
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the 50 most dysregulated genes in mEH KO and sEH KO liv-
ers). In WT liver, the gene expression ratio for Ephx1:Ephx2 
(with Ephx1 encoding for mEH protein and Ephx2 for sEH 
protein, respectively) was 1:2.6 (left columns in Fig. 6a, b). 
In mEH KO liver, gene expression of Ephx2 was 1.4-fold 
higher relative to WT liver (Fig. 6b), indicating that transcrip-
tional upregulation probably underlies the higher sEH protein 
expression and activity observed in mEH KO liver. Surpris-
ingly, gene expression of Ephx1 was also enhanced by factor 
1.35 in sEH KO liver relative to WT (Fig. 6a). Genes encod-
ing for other EHs, e.g., Ephx3 and Ephx4 were not present in 
any of the analyzed liver transcriptomes. Next, we focused on 
the changes in the expression levels of Cyp genes. We found 
the same 64 Cyp genes expressed in detectable amounts (sta-
tistically significant above background level) in WT, mEH 
KO, and sEH KO liver (Suppl. Table 5). Cyp2e1 was by far 
the most abundant, irrespective of the genotype (Table 1). 
While most CYP proteins probably exert at least some epox-
ygenase activity (Kaspera and Totah 2009), members of the 
Cyp2c and Cyp2j subfamilies are commonly noted to exert the 
highest epoxygenase activity with AA. Which epoxygenase 
isoforms are particularly efficient in oxidizing linoleic acid, 
the precursor lipid for EpOMEs, is still unknown. Whereas 
the Cyp2c family was represented by 13 isoforms in C57BL/6 
liver (2c29, 2c37, 2c38, 2c39, 2c40, 2c44, 2c50, 2c54, 2c55, 
2c67, 2c68, 2c69, 2c70), only 3 Cyp2j isoenzymes were 
present (2j5, 2j6 and 2j9). Overall, effects on Cyp2c and 
Cyp2j isoforms were disparate with certain isoforms either 
reduced, upregulated, or unchanged in KO relative to WT 
livers (Fig. 6c and Suppl. Table 5). However, the most abun-
dant Cyp genes were dysregulated in parallel manner in both 
KO livers: Cyp2c70 and Cyp2j5 were unchanged, Cyp2c29 
and Cyp2c50 significantly increased, and Cyp2c68 decreased 
relative to WT (Fig. 6c, Table 1, and Suppl. Table 5). Cyp4a 
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and Cyp4f isoforms code for ω-hydroxylases, which catalyze 
the formation of 20-HETE, a strong vasoconstrictor, and in 
many tissues the antagonist of EET-mediated actions. sEH 
deficiency mainly increased the expression of several isoen-
zymes (4a31, 4a32, 4f13, 4f15 with p < 0.05 as cut-off). Loss 
of mEH led to more inconsistent effects, causing upregula-
tion of Cyp4f13 and Cyp4f15 and suppression of Cyp4a31 
(p < 0.05 as cut-off; Fig. 6d and Suppl. Table 5). Notably, 
neither mEH nor sEH deficiency affected the expression of the 
most abundant 20-HETE synthase genes such as Cyp4a12a 
and Cyp4a12b (see Suppl. Table 5 for details).
Discussion
Regarding the quantitative contribution to hepatic FA epox-
ide hydrolysis, the odds are clearly in favor of sEH: Based on 
the transcriptome data presented in this study, sEH expres-
sion is approximately 2.5 times higher than mEH expres-
sion in mouse liver and under saturating conditions, purified 
mouse sEH is between 24 times (8,9-EET) and 800 times 
(14,15-EET) faster in hydrolyzing the respective epoxides 
compared to mEH. Nevertheless, we found the plasma levels 
for two FA epoxides substantially decreased in mEH KO 
relative to WT animals, providing strong evidence for a sub-
stantial role of mEH in the metabolism of epoxy FAs in vivo. 
Moreover, the strong correlation between FA plasma levels 
and hepatic EH hydrolysis rates (Schuck et al. 2014) points 
to hepatic mEH as important player in FA hydrolysis.
Indeed, hepatic mEH exerts substantial FA epoxide 
hydrolase activity, as sEH KO livers still synthesize 65% 
(Fig. 4; Suppl. Table 2) of DHETs and DiHOMEs formed 
under the same conditions in WT livers. Several lines of 
evidence suggest that it is mEH that with high probability 
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mediates the residual EH activity in sEH KO liver: (1) 
sEH deficiency in sEH KO mice was confirmed on protein 
level [sEH protein was no longer detectable (Luria et al. 
2007)]; (2) genes of other known EHs were not expressed 
in C57BL/6 liver, excluding the possibility that EH3 or EH4 
account for the hydrolysis; and, most importantly, (3) EH 
activity in sEH KO microsomes could almost completely 
be blocked by a combination of mEH blockers (Fig. 5d). 
There is a low residual probability, however, that one of the 
upregulated genes in sEH KO liver (Suppl. Table 4), whose 
protein product is unknown, encodes for a so far uncharac-
terized EH.
Interestingly, a recent report corroborated our results 
that sEH KO liver exhibits high EH activity. In the study by 
Zhu and colleagues (Zhu et al. 2016), hepatic levels of FA 
epoxides and diols were determined by subjecting WT and 
sEH KO livers to alkaline lysis; DHET and DiHOME levels 
were similar between WT and sEH KO with the exception 
of 14,15-DHET, which was significantly lower in sEH KO 
liver. We also found strong variations in mEH-mediated 
diol formation in sEH KO liver depending on the parental 
epoxides. The difference between the respective formation 
rates in WT and sEH KO was highest for 12,13-DiHOME, 
followed by 5,6-DHET and 14,15-DHET, which is in accord 
with the fact that the respective epoxides are the least pre-
ferred substrates of mEH. The difference in the formation 
rates between WT and sEH KO was comparatively small for 
8,9- and 11,12-DHET as well as for 9,10-DiHOME, indicat-
ing that the parental epoxides constitute the best substrates 
for mEH in the present series of compounds. However, 
mEH KO plasma only showed reduced hydrolysis ratios for 
8,9-DHET:EET and 9,10-DiHOME:EpOME. Thus, if both 
enzymes are present in liver, sEH is probably the predomi-
nant EH for the conversion of 5,6-, 11,12-, and 14,15-EET 
as well as 12,13-EpOME and mEH the predominant EH for 
hydrolyzing 8,9-EET and 9,10-EpOME.
The preference profile for sEH indicates a low catalytic 
efficiency (reflecting the enzyme’s preference) for 8,9-EET, 
but a particularly high one for 9,10-EpOME (Morisseau 
et al. 2010). In hepatocytes, where both EH are present, sEH 
should hence dominate the hydrolysis of 9,10-EpOME due 
to its higher activity with this substrate. Despite the strong 
relationship between hepatic EH activity and FA hydroly-
sis rates in plasma, it may be that plasma 9,10-DiHOME is 
formed in other cells than hepatocytes. These cells might 
possibly only express mEH. Classically, DiHOMEs are 
formed during neutrophilic outburst (Hayakawa et al. 1986) 
and by adipocytes (Lynes et al. 2017). mEH expression 
seems principally to be more widespread compared to the 
one of sEH, comprising not necessarily more tissues, but 
cell types. Notably, mEH is found in some immunoreactive 
cells such as the liver-resident macrophages (Kupffer cells) 
and in brain in activated microglia (unpublished data) as 
well as in endothelial cells of many tissues (Marowsky et al. 
2009)—with none of these cell types expressing sEH to our 
knowledge. However, if any of these mEH-expressing cells 
synthesize DiHOMEs remains to be elucidated.
The transcriptome data provide further proof for a critical 
role of mEH in endogenous lipid metabolism. Loss of either 
EH induced the transcriptional upregulation of the residual 
EH gene to a similar degree (1.3- and 1.4-fold, respectively), 
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Fig. 6  Changes in genes of the CYP-epoxygenase–EH pathway in 
mEH KO and sEH KO liver transcriptome. a Ephx1, encoding for 
the mEH protein, is 1.35-fold upregulated in sEH KO relative to WT 
liver. b Ephx2, encoding for the sEH protein, is 1.4-fold upregulated 
in mEH KO relative to WT liver. Note, that in WT liver Ephx2 is 2.5 
times more abundant than Ephx1 (n  =  3 for each genotype, 1-way 
ANOVA followed by Bonferroni post tests; only significant differ-
ences between WT and KO are indicated). c Expression changes 
in Cyp2c and Cyp2j genes, encoding for epoxygenases, are shown 
as Log2 ratio of the respective KO over WT; the Cyp gene with the 
strongest change in expression (Cyp2a4) is displayed for comparison. 
A 1.5-fold increase relative to WT is represented by 0.5 on the Log2 
ratio scale, e.g., see the Cyp2c44  bar for mEH KO. Only Cyp2c/2j 
genes with statistically significant changes (cut-off p < 0.05) relative 
to WT are depicted as bar graphs. Note that for several of these genes, 
expression changes occur in parallel for both KO livers. d The same 
as c for ω-hydroxylase genes. Expression changes in the 20-HETE 
synthases only occur with low-expression ω-hydroxylase genes
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which is indicative of the notion that they share the same 
substrates. However, with regard to xenobiotic substrates, 
mEH and sEH display complementarity: Only sEH can 
hydrolyze trans-substituted compounds, but is restricted 
to “slim” substrates, while mEH is capable of hydrolyzing 
bulky hydrophobic substrates as long as they are not trans-
substituted. This suggests that their shared substrates are 
rather of endogenous origin, e.g., FA epoxides.
Moreover, the principal CYPs and CYP epoxygenases 
were dysregulated in parallel manner in both KO transcrip-
tomes. The by far most abundant Cyp in C57BL/6 WT liver 
(Cyp2e1) was increased in mEH KO (1.8-fold) and sEH 
KO (1.6-fold) relative to WT (Suppl. Table 5). According 
to our transcriptome analysis, Cyp2c70, Cyp2c29, Cyp2c50, 
Cyp2j5, and Cyp2c68 constitute the five most abundant 
epoxygenases in C57BL/6 WT liver, a result largely in line 
with previous studies (Schuck et al. 2014; Theken et al. 
2011). The expression of these five key epoxygenases was 
altered in identical manner in both KO mice. However, since 
gene expression changes occurred in both directions, it was 
impossible to deduce if EH loss leads as net effect to less or 
more hepatic epoxygenase activity. The biochemical assays 
yielded conflicting results: In assays with mEH and sEH KO 
microsomes, the sum of generated [EETs and DHETs] was 
similar between genotypes, suggesting that the combined 
capacity of epoxygenases and EHs was unaltered between 
the two KO strains. However, in experiments with liver tis-
sue, mEH KO liver formed substantially more diols (epox-
ides were not detectable), whereas sEH KO liver formed less 
[epoxides and diols] compared to WT. It should be noted 
that sEH levels differ between these two preparations (the 
content of the cytosol-residing sEH is reduced in microso-
mal fractions, but not in liver homogenates) and that hence 
sEH or diol levels may influence the availability of AA and 
epoxygenase activity.
Table 1  Expression of Cyp 
genes in C57BL/6 liver in 
descending order, normalized to 
Gapdh gene expression
Isoenzyme
Cyp2e1 13.53
Cyp3a11 5.81
Cyp2f2 2.85
Cyp2d9 2.76
Cyp2c70 2.72
Cyp2c29 2.60
Cyp2c50 2.02
Cyp2j5 1.77
Cyp2a12 1.54
Cyp1a2 1.51
Cyp2d26 1.41
Cyp2c67 1.18
Cyp2d10 1.16
Cyp4v3 1.14
Cyp2a5 1.10
Cyp2c68 1.07
Cyp27a1 1.00
Cyp7b1 0.92
Cyp2c54 0.87
Cyp2c44 0.86
Cyp3a25 0.80
Cyp4f14 0.77
Cyp4a12a 0.70
Cyp2c37 0.63
Cyp51 0.60
Cyp8b1 0.60
Cyp2d22 0.44
Cyp3a13 0.39
Cyp2c40 0.29
Cyp7a1 0.29
Cyp2j6 0.25
Cyp4a12b 0.22
Cyp4f15 0.216
Cyp4a10 0.195
Cyp2a4 0.179
Cyp2c69 0.150
Cyp4f13 0.122
Cyp2d40 0.111
Cyp2c38 0.086
Cyp39a1 0.067
Cyp4a14 0.063
Cyp3a59 0.050
Cyp2r1 0.043
Cyp2u1 0.037
Cyp4a32 0.037
Cyp20a1 0.031
Cyp17a1 0.026
Cyp2c55 0.023
Cyp4b1 0.022
Cyp4f17 0.015
Cyp26b1 0.014
Table 1  (continued) Isoenzyme
Cyp4a31 0.013
Cyp26a1 0.009
Cyp2j9 0.008
Cyp4f16 0.006
Cyp2c39 0.006
Cyp2a22 0.004
Cyp2g1 0.004
Cyp2b10 0.003
Cyp1a1 0.003
Cyp1b1 0.002
Cyp2s1 0.002
Cyp2d12 0.002
Cyp2b9 0.001
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The vasoconstrictor 20-HETE is generated by Cyp4a 
and Cyp4f isoforms (also termed ω-hydroxylases) and com-
monly considered to play an opposing role to the vasodila-
tory EETs. sEH deficiency leads to transcriptional upregula-
tion of 20-HETE generating CYPs exclusively in kidney, but 
not in liver (Luria et al. 2007; Zhu et al. 2016). We found 
that the most abundantly expressed ω-hydroxylases with 
reportedly high catalytic efficiency with AA [Cyp4a12a, 
Cyp4a12b (Muller et  al. 2007), Cyp4f15 (Schuck et  al. 
2014)] are either not affected by loss of mEH or sEH or 
upregulated in both KO livers (Cyp4f15) compared to WT. 
The AA capacity assay further revealed that the hepatic 
formation rate for 20-HETE was similar across genotypes, 
which is consistent with earlier studies (Luria et al. 2007; 
Zhu et al. 2016). Interestingly, in liver and lung, EETs were 
reported to exert vasoconstricting rather than vasodilatory 
effects, thus not counteracting 20-HETE action but rather 
adding to it (Sacerdoti et al. 2015). This might be a possible 
reason why the generation of 20-HETE is unchanged in sEH 
KO relative to WT liver, but increased in sEH KO kidney.
Our data also indicate that certain conditions modulate 
the contribution of mEH to FA epoxide hydrolysis. Notably, 
low epoxide levels favor mEH-mediated over sEH-mediated 
hydrolysis. This is possibly due to the lower KM values 
(translating into higher affinity) displayed by mEH with all 
EETs compared to sEH (Decker et al. 2012). mEH-mediated 
hydrolysis may profit from one additional fact: The enzyme 
is localized in close physical proximity to expoxygenases to 
mEH in intact cells, allowing probably for the direct transfer 
of the substrate from epoxygenases in a process called sub-
strate channeling (Orjuela et al. 2017). This effect, however, 
only comes into full play when the cell compartmentaliza-
tion is left intact (e.g., with untreated cells and in vivo). In 
liver homogenates and microsomes, where cell compartmen-
talization is largely destroyed, epoxides may diffuse more 
easily and thus increase the probability for being subjected 
to sEH-mediated hydrolysis. This may explain why mEH 
effects are mainly seen in vivo (Marowsky et al. 2016), but 
not in capacity assays with homogenates or cellular frac-
tion with excess AA (Luria et al. 2007). Furthermore, the 
observed mEH activity with FA epoxides might explain 
recent findings that human mEH polymorphisms correlate 
with the susceptibility to develop preeclampsia (Zusterzeel 
et al. 2001).
Taken together, our data clearly support a significant role 
for mEH in lipid signaling, particularly in the hydrolysis 
of 8,9-EET and 9,10-EpOME. Yet it should be emphasized 
that mEH-mediated hydrolysis does not extend to endo-
cannabinoids, as suggested recently (Nithipatikom et al. 
2014), because the reported hydrolytic activity with 2-Ara-
chidonoylglycerol was not attributable to mEH (Arand and 
Marowsky 2016). Further studies are warranted to define the 
exact role of mEH in endogenous FA hydrolysis and in the 
regulation of physiological processes related to this.
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